comparemela.com

Latest Breaking News On - Ronalda rader - Page 1 : comparemela.com

Cell Gene Therapy Bioprocessing Demand For Better Process Control Expertise CMOs

Cell & Gene Therapy Bioprocessing: Demand For Better Process Control, Expertise & CMOs By Ronald A. Rader and Eric S. Langer, BioPlan Associates, Inc. Manufacturing capacity for both cellular therapies and gene therapy viral vectors remains in short supply.  From our research, including interviews with developers, there is a current and worsening capacity crunch. BioPlan Associates, Inc. annually surveys biopharmaceutical manufacturing professionals and publishes data on capacity and other industry concerns. 1 The survey, now in its 18 th year, includes 147 end users’ responses and also provides input from 101 suppliers/vendors worldwide. This year, we find that the industry continues to demand innovative solutions from its suppliers in key areas, but these can often be slow to develop. 

Bioprocessing Year In Review 11 Key Trends Accelerated By COVID-19

Bioprocessing Year In Review: 11 Key Trends Accelerated By COVID-19 By Ronald A. Rader and Eric S. Langer, BioPlan Associates, Inc. Over the past 17 years we have identified a number of trends that are impacting bioprocessing and biopharmaceuticals manufacturing, the majority of which have promised positive outcomes.  With the COVID-19 crisis, many of these ongoing trends have been accelerated. Although it seems we may now be seeing the light at the end of the COVID tunnel, some of the effects of the pandemic on bioprocessing and vaccines manufacturing may result in permanent changes. Major concerns, even pre-pandemic, were continued cost-cutting and often related mergers and acquisitions, but even this trend appears to be slowing. Staffing problems, on the other hand will only get worse, especially with rapid growth in foreign bioprocessing and new cellular and gene therapies-associated capacity.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.